- Hong Kong
- /
- Healthtech
- /
- SEHK:2361
Sinohealth Holdings (HKG:2361) Will Pay A Larger Dividend Than Last Year At CN¥0.12
Sinohealth Holdings Limited's (HKG:2361) dividend will be increasing from last year's payment of the same period to CN¥0.12 on 25th of September. This will take the annual payment to 3.9% of the stock price, which is above what most companies in the industry pay.
Sinohealth Holdings' Payment Could Potentially Have Solid Earnings Coverage
Impressive dividend yields are good, but this doesn't matter much if the payments can't be sustained. The last dividend was quite easily covered by Sinohealth Holdings' earnings. This means that a large portion of its earnings are being retained to grow the business.
Over the next year, EPS could expand by 8.7% if recent trends continue. If the dividend continues on this path, the payout ratio could be 73% by next year, which we think can be pretty sustainable going forward.
Check out our latest analysis for Sinohealth Holdings
Sinohealth Holdings Is Still Building Its Track Record
The dividend has been pretty stable looking back, but the company hasn't been paying one for very long. This makes it tough to judge how it would fare through a full economic cycle. Since 2023, the dividend has gone from CN¥0.0348 total annually to CN¥0.11. This means that it has been growing its distributions at 78% per annum over that time. It is always nice to see strong dividend growth, but with such a short payment history we wouldn't be inclined to rely on it until a longer track record can be developed.
The Dividend Has Growth Potential
Some investors will be chomping at the bit to buy some of the company's stock based on its dividend history. It's encouraging to see that Sinohealth Holdings has been growing its earnings per share at 8.7% a year over the past three years. Since earnings per share is growing at an acceptable rate, and the payout policy is balanced, we think the company is positioning itself well to grow earnings and dividends in the future.
Our Thoughts On Sinohealth Holdings' Dividend
Overall, it's great to see the dividend being raised and that it is still in a sustainable range. The payout ratio looks good, but unfortunately the company's dividend track record isn't stellar. The payment isn't stellar, but it could make a decent addition to a dividend portfolio.
Companies possessing a stable dividend policy will likely enjoy greater investor interest than those suffering from a more inconsistent approach. Still, investors need to consider a host of other factors, apart from dividend payments, when analysing a company. You can also discover whether shareholders are aligned with insider interests by checking our visualisation of insider shareholdings and trades in Sinohealth Holdings stock. Looking for more high-yielding dividend ideas? Try our collection of strong dividend payers.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About SEHK:2361
Sinohealth Holdings
Provides healthcare solutions for sales and marketing needs of medical product manufacturer clients in Mainland China, the Netherland, England, Hong Kong, Singapore, and internationally.
Flawless balance sheet and good value.
Similar Companies
Market Insights
Community Narratives
